Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Lynn A. Lambert"'
Autor:
Puthupparampil V. Scaria, Nicole Roth, Kim Schwendt, Olga V. Muratova, Nada Alani, Lynn E. Lambert, Emma K. Barnafo, Christopher G. Rowe, Irfan U. Zaidi, Kelly M. Rausch, David L. Narum, Benjamin Petsch, Patrick E. Duffy
Publikováno v:
npj Vaccines, Vol 9, Iss 1, Pp 1-10 (2024)
Abstract Malaria transmission-blocking vaccines (TBV) are designed to inhibit the sexual stage development of the parasite in the mosquito host and can play a significant role in achieving the goal of malaria elimination. Preclinical and clinical stu
Externí odkaz:
https://doaj.org/article/c1b01465fd85446dbc27c45b0c566753
Autor:
Palak N. Patel, Thayne H. Dickey, Ababacar Diouf, Nichole D. Salinas, Holly McAleese, Tarik Ouahes, Carole A. Long, Kazutoyo Miura, Lynn E. Lambert, Niraj H. Tolia
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-16 (2023)
Abstract Apical membrane antigen 1 (AMA1) is a key malaria vaccine candidate and target of neutralizing antibodies. AMA1 binds to a loop in rhoptry neck protein 2 (RON2L) to form the moving junction during parasite invasion of host cells, and this co
Externí odkaz:
https://doaj.org/article/e25790efa50d468795dd8e573113c770
Autor:
Nichole D. Salinas, Rui Ma, Thayne H. Dickey, Holly McAleese, Tarik Ouahes, Carole A. Long, Kazutoyo Miura, Lynn E. Lambert, Niraj H. Tolia
Publikováno v:
npj Vaccines, Vol 8, Iss 1, Pp 1-11 (2023)
Abstract Malaria transmission-blocking vaccines (TBVs) reduce disease transmission by breaking the continuous cycle of infection between the human host and the mosquito vector. Domain 1 (D1) of Pfs230 is a leading TBV candidate and comprises the majo
Externí odkaz:
https://doaj.org/article/2ab6d2c8491e429d86c474230614ad0e
Autor:
Nicholas J. MacDonald, Kavita Singh, Karine Reiter, Vu Nguyen, Richard Shimp, Apostolos G. Gittis, Beth Chen, Martin Burkhardt, Baoshan Zhang, Zhixiong Wang, Raul Herrera, Mackenzie Moler, Duck-Yeon Lee, Sachy Orr-Gonzalez, Jessica Herrod, Lynn E. Lambert, Kelly M. Rausch, Olga Muratova, David S. Jones, Yimin Wu, Albert J. Jin, David N. Garboczi, Patrick E. Duffy, David L. Narum
Publikováno v:
npj Vaccines, Vol 8, Iss 1, Pp 1-9 (2023)
Abstract Development of a malaria vaccine that blocks transmission of different parasite stages to humans and mosquitoes is considered critical for elimination efforts. A vaccine using Pfs25, a protein on the surface of zygotes and ookinetes, is unde
Externí odkaz:
https://doaj.org/article/744dd43cb85546b1a8f8ee76086ef8c5
Autor:
Nichole D. Salinas, Rui Ma, Holly McAleese, Tarik Ouahes, Carole A. Long, Kazutoyo Miura, Lynn E. Lambert, Niraj H. Tolia
Publikováno v:
Vaccines, Vol 12, Iss 5, p 546 (2024)
Malaria is caused by eukaryotic protozoan parasites of the genus Plasmodium. There are 249 million new cases and 608,000 deaths annually, and new interventions are desperately needed. Malaria vaccines can be divided into three categories: liver stage
Externí odkaz:
https://doaj.org/article/26f63ef025694a5f811a1f546e35c75f
Autor:
Thayne H. Dickey, Richi Gupta, Holly McAleese, Tarik Ouahes, Sachy Orr-Gonzalez, Rui Ma, Olga Muratova, Nichole D. Salinas, Jen C. C. Hume, Lynn E. Lambert, Patrick E. Duffy, Niraj H. Tolia
Publikováno v:
npj Vaccines, Vol 8, Iss 1, Pp 1-10 (2023)
Abstract A malaria vaccine that blocks parasite transmission from human to mosquito would be a powerful method of disrupting the parasite lifecycle and reducing the incidence of disease in humans. Pfs48/45 is a promising antigen in development as a t
Externí odkaz:
https://doaj.org/article/08492bc9918f41c297b57ea2d425e412
Autor:
Kelly M. Rausch, Emma K. Barnafo, Lynn E. Lambert, Olga Muratova, J. Patrick Gorres, Charles Anderson, David L. Narum, Yimin Wu, Robert D. Morrison, Irfan Zaidi, Patrick E. Duffy
Publikováno v:
iScience, Vol 26, Iss 7, Pp 107192- (2023)
Summary: Malaria transmission-blocking vaccine candidates Pfs25-EPA and Pfs230D1-EPA target sexual stage development of Plasmodium falciparum parasites in the mosquito host, thereby reducing mosquito infectivity. When formulated on Alhydrogel, Pfs25-
Externí odkaz:
https://doaj.org/article/885b8dce5bd44683bfd7714c5ef347cc
Autor:
Sumana Chakravarty, Melanie J. Shears, Eric R. James, Urvashi Rai, Natasha KC, Solomon Conteh, Lynn E. Lambert, Patrick E. Duffy, Sean C. Murphy, Stephen L. Hoffman
Publikováno v:
Malaria Journal, Vol 21, Iss 1, Pp 1-11 (2022)
Abstract Background Plasmodium falciparum (Pf) sporozoite (SPZ) vaccines are the only candidate malaria vaccines that induce > 90% vaccine efficacy (VE) against controlled human malaria infection and the only malaria vaccines to have achieved reprodu
Externí odkaz:
https://doaj.org/article/4fbb2445f2d24adaba6081405b24db41
Autor:
Thayne H. Dickey, Rui Ma, Sachy Orr-Gonzalez, Tarik Ouahes, Palak Patel, Holly McAleese, Brandi Butler, Elizabeth Eudy, Brett Eaton, Michael Murphy, Jennifer L. Kwan, Nichole D. Salinas, Michael R. Holbrook, Lynn E. Lambert, Niraj H. Tolia
Publikováno v:
Cell Reports, Vol 42, Iss 3, Pp 112266- (2023)
Summary: Waning immunity and emerging variants necessitate continued vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Improvements in vaccine safety, tolerability, and ease of manufacturing would benefit these efforts
Externí odkaz:
https://doaj.org/article/2f8a750ed97546e7a5f0d5c5d170d242
Autor:
Puthupparampil V. Scaria, Chris G. Rowe, Beth B. Chen, Thayne H. Dickey, Jonathan P. Renn, Lynn E. Lambert, Emma K. Barnafo, Kelly M. Rausch, Niraj H. Tolia, Patrick E. Duffy
Publikováno v:
iScience, Vol 25, Iss 8, Pp 104739- (2022)
Summary: Several effective SARS-CoV-2 vaccines have been developed using different technologies. Although these vaccines target the isolates collected early in the pandemic, many have protected against serious illness from newer variants. Nevertheles
Externí odkaz:
https://doaj.org/article/3888040905054b98b1ef53b0ef9b1c20